PMGC subsidiary NorthStrive signs exclusive license for EL-22/EL-32 in animal health

PMGC Holdings Inc.

Definitive license with Modulant Biosciences for myostatin-engineered probiotic EL-22 and EL-32.
Modulant gets exclusive, royalty-bearing, sublicensable license for non-human animal health worldwide except Korea.
Modulant pays value (undisclosed) and handles development, manufacturing, regulatory, commercialization.
License excludes human pharmaceutical applications; shared ownership of improvements.
Follows binding term sheet from May 2025; no assurance of commercial success.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.